Real-world data show that Enhertu (fam-trastuzumab deruxtecan-nxki) was tolerated as well in the community setting, where patients had higher disease burden, as in the clinical trial setting, ...

Nearly 1 in 3 patients with connective tissue disease-associated interstitial lung disease will develop progressive pulmonary fibrosis.

The Pulmonary Fibrosis Foundation's Care Center Network has grown to include 96 sites in 40 states as part of its first expansion since 2023, marking a milestone in strengthening access to ...

Rural ILD patients experience significant diagnostic and treatment delays compared to urban counterparts, highlighting access challenges. Telehealth shows promise in improving access to ILD care, ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Concurrent pulmonary arterial hypertension and ...

The prevalence of interstitial lung disease (ILD) across connective tissue disorders (CTDs) and its persistent standing as a leading cause of death in patients with CTDs challenge rheumatologists to ...

New-onset interstitial lung disease (ILD) in patients with systemic sclerosis (SSc) occurred at a rate of 3.83 cases per 100 person-years, with detection noted up to 10 years post-negative screening ...

Treatment regimens of steroids and disease-modifying antirheumatic drugs were effective in reducing the short-term death rate among patients with acute exacerbation of interstitial lung disease ...